Boston Scientific reported that it has received approval from the U.S. Food and Drug Administration to market its Apex percutaneous transluminal coronary angioplasty (PTCA) dilatation catheter.

The device is a pre-dilatation balloon catheter developed specifically to address physicians' needs in treating challenging atherosclerotic lesions, Boston Scientific said. It is available for distribution in both Monorail and Over-The-Wire catheter platforms, according to the company.